Company intelligence / Profile preview

Careseng

Unknown*, Taiwan Province, Chinashiyunwellnesscentre.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Careseng Biotech Co. Ltd., based in Taiwan Province, China, developed Careseng 1370—a botanical drug candidate derived from concentrated ginseng extracts—intended to treat chemotherapy-induced myelosuppression in advanced NSCLC patients. The company sponsored a Phase I/IIa clinical trial that was later withdrawn prior to completion. Preclinical data suggest possible anti-cancer effects across multiple tumor types via apoptosis induction and inhibition of angiogenesis/multidrug resistance mechanisms.

Therapeutic areas: Oncology
Modalities: Botanical extract-based therapeutics, specifically ginseng-derived compounds
Industry: Biotech

Drug pipeline

1 asset

careseng

Pre-clinical

Indications: Breast cancer, Liver cancer, Colon cancer, Prostate cancer, Lung cancer, Pancreatic cancer, Brain cancer

Beyond the preview

Go deeper on Careseng.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Careseng.

Explore the full profile